2026 Payor Denial Impact Report: Diagnostics Edition
New XiFin Data on Denial Trends, Appeal Revenue, and AI in Diagnostics Revenue Cycle Management
An analysis of more than 30 million diagnostic claims across clinical laboratory, hospital outreach, molecular diagnostics and genomics, and anatomic pathology.
The 2026 Payor Denial Impact Report examines how changing payor policies, documentation requirements, and machine-speed adjudication are affecting diagnostics revenue cycle management (RCM).
Based on claims with 2025 dates of service, the report identifies where denials are increasing, which appeals are generating reimbursement, and how diagnostic organizations can respond with automation, artificial intelligence (AI), and human expertise.
The overall denial rate in the analysis increased to 11.2% in 2025 from 8.0% in 2024, reversing two years of improvement. The causes varied by segment:
- Bundling edits led denials in clinical and hospital outreach laboratories
- Prior authorization and coverage policies created significant pressure in molecular diagnostics and genomics
- Coordination-of-benefits denials rose sharply in anatomic pathology
Appeals also remained a measurable source of recovered revenue, with success rates, average payments, and the value of additional attempts varying by segment.
What Does the Report Cover?
The report provides diagnostics, finance, operations, and revenue cycle leaders with data and guidance on:
- Denial trends by payor group and diagnostics segment
- Appeal success, payment value, and additional attempts
- Documentation requirements affecting reimbursement
- Coding, bundling, downcoding, and coverage policy changes
- AI-supported appeals, document handling, payor response interpretation, and exception prioritization
- An actionable denial and appeals playbook
Key Findings From More Than 30 Million Diagnostic Claims
- Denial Rates Increased Across Every Payor Group Analyzed
- Bundling Dominated Laboratory Denials
- Molecular Diagnostics Faced Prior Authorization and Coverage Pressure
- Coordination-of-Benefits Denials Rose in Anatomic Pathology
- Additional Appeal Attempts Recovered Revenue
- Appeal Economics Varied by Segment
How Can AI Support Diagnostics Denial Management?
The report identifies four workflows in which AI can help teams manage increasing complexity:
- Appeal preparation: Research policies, assemble documentation, and create patient- and payor-specific appeal packages
- Document handling: Extract, classify, label, and route records for authorization, claim, appeal, and audit workflows
- Payor response interpretation: Translate inconsistent payor messages into actionable reason codes and workflows
- Exception prioritization: Rank errors and denials by value, urgency, and likelihood of reimbursement
Human experts remain responsible for guardrails, escalation, approval, and consequential decisions. The recommended operating model is AI plus people, not AI alone.
Download the Report
Use the report to:
- Benchmark denial trends across diagnostics segments
- Reevaluate appeal thresholds and additional attempts
- Strengthen documentation before claim submission
- Identify high-value workflows for automation and AI
- Prioritize immediate, quarterly, and strategic actions